Heart rate-induced modifications of concentric left ventricular hypertrophy: Exploration of a novel therapeutic concept

Franziska J. Klein, Stephen Bell, K. Elisabeth Runte, Robert Lobel, Takamuru Ashikaga, Lilach O Lerman, Martin M. LeWinter, Markus Meyer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Lowering the heart rate is considered to be beneficial in heart failure (HF) with reduced ejection fraction (HFrEF). In a dilated left ventricle (LV), pharmacological heart rate lowering is associated with a reduction in LV chamber size. In patients with HFrEF, this structural change is associated with better survival. HF with preserved ejection fraction (HFpEF) is increasingly prevalent but, so far, without any evidence-based treatment. HFpEF is typically associated with LV concentric remodeling and hypertrophy. The effects of heart rate on this structural phenotype are not known. Analogous with the benefits of a low heart rate on a dilated heart, we hypothesized that increased heart rates could lead to potentially beneficial remodeling of a concentrically hypertrophied LV. This was explored in an established porcine model of concentric LV hypertrophy and fibrosis. Our results suggest that a moderate increase in heart rate can be used to reduce wall thickness, normalize LV chamber volumes, decrease myocardial fibrosis, and improve LV compliance. Our results also indicate that the effects of heart rate can be titrated, are reversible, and do not induce HF. These findings may provide the rationale for a novel therapeutic approach for HFpEF and its antecedent disease substrate.

Original languageEnglish (US)
Pages (from-to)H1031-H1039
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume311
Issue number4
DOIs
StatePublished - 2016

Fingerprint

Left Ventricular Hypertrophy
Heart Ventricles
Heart Rate
Heart Failure
Hypertrophy
Therapeutics
Fibrosis
Ventricular Remodeling
Compliance
Swine
Pharmacology
Phenotype
Survival

Keywords

  • Heart rate
  • Hypertrophy
  • Pacemaker
  • Remodelling

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Heart rate-induced modifications of concentric left ventricular hypertrophy : Exploration of a novel therapeutic concept. / Klein, Franziska J.; Bell, Stephen; Runte, K. Elisabeth; Lobel, Robert; Ashikaga, Takamuru; Lerman, Lilach O; LeWinter, Martin M.; Meyer, Markus.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 311, No. 4, 2016, p. H1031-H1039.

Research output: Contribution to journalArticle

Klein, Franziska J. ; Bell, Stephen ; Runte, K. Elisabeth ; Lobel, Robert ; Ashikaga, Takamuru ; Lerman, Lilach O ; LeWinter, Martin M. ; Meyer, Markus. / Heart rate-induced modifications of concentric left ventricular hypertrophy : Exploration of a novel therapeutic concept. In: American Journal of Physiology - Heart and Circulatory Physiology. 2016 ; Vol. 311, No. 4. pp. H1031-H1039.
@article{3bce7556ad0a4b908d911dde9167773a,
title = "Heart rate-induced modifications of concentric left ventricular hypertrophy: Exploration of a novel therapeutic concept",
abstract = "Lowering the heart rate is considered to be beneficial in heart failure (HF) with reduced ejection fraction (HFrEF). In a dilated left ventricle (LV), pharmacological heart rate lowering is associated with a reduction in LV chamber size. In patients with HFrEF, this structural change is associated with better survival. HF with preserved ejection fraction (HFpEF) is increasingly prevalent but, so far, without any evidence-based treatment. HFpEF is typically associated with LV concentric remodeling and hypertrophy. The effects of heart rate on this structural phenotype are not known. Analogous with the benefits of a low heart rate on a dilated heart, we hypothesized that increased heart rates could lead to potentially beneficial remodeling of a concentrically hypertrophied LV. This was explored in an established porcine model of concentric LV hypertrophy and fibrosis. Our results suggest that a moderate increase in heart rate can be used to reduce wall thickness, normalize LV chamber volumes, decrease myocardial fibrosis, and improve LV compliance. Our results also indicate that the effects of heart rate can be titrated, are reversible, and do not induce HF. These findings may provide the rationale for a novel therapeutic approach for HFpEF and its antecedent disease substrate.",
keywords = "Heart rate, Hypertrophy, Pacemaker, Remodelling",
author = "Klein, {Franziska J.} and Stephen Bell and Runte, {K. Elisabeth} and Robert Lobel and Takamuru Ashikaga and Lerman, {Lilach O} and LeWinter, {Martin M.} and Markus Meyer",
year = "2016",
doi = "10.1152/ajpheart.00301.2016",
language = "English (US)",
volume = "311",
pages = "H1031--H1039",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Heart rate-induced modifications of concentric left ventricular hypertrophy

T2 - Exploration of a novel therapeutic concept

AU - Klein, Franziska J.

AU - Bell, Stephen

AU - Runte, K. Elisabeth

AU - Lobel, Robert

AU - Ashikaga, Takamuru

AU - Lerman, Lilach O

AU - LeWinter, Martin M.

AU - Meyer, Markus

PY - 2016

Y1 - 2016

N2 - Lowering the heart rate is considered to be beneficial in heart failure (HF) with reduced ejection fraction (HFrEF). In a dilated left ventricle (LV), pharmacological heart rate lowering is associated with a reduction in LV chamber size. In patients with HFrEF, this structural change is associated with better survival. HF with preserved ejection fraction (HFpEF) is increasingly prevalent but, so far, without any evidence-based treatment. HFpEF is typically associated with LV concentric remodeling and hypertrophy. The effects of heart rate on this structural phenotype are not known. Analogous with the benefits of a low heart rate on a dilated heart, we hypothesized that increased heart rates could lead to potentially beneficial remodeling of a concentrically hypertrophied LV. This was explored in an established porcine model of concentric LV hypertrophy and fibrosis. Our results suggest that a moderate increase in heart rate can be used to reduce wall thickness, normalize LV chamber volumes, decrease myocardial fibrosis, and improve LV compliance. Our results also indicate that the effects of heart rate can be titrated, are reversible, and do not induce HF. These findings may provide the rationale for a novel therapeutic approach for HFpEF and its antecedent disease substrate.

AB - Lowering the heart rate is considered to be beneficial in heart failure (HF) with reduced ejection fraction (HFrEF). In a dilated left ventricle (LV), pharmacological heart rate lowering is associated with a reduction in LV chamber size. In patients with HFrEF, this structural change is associated with better survival. HF with preserved ejection fraction (HFpEF) is increasingly prevalent but, so far, without any evidence-based treatment. HFpEF is typically associated with LV concentric remodeling and hypertrophy. The effects of heart rate on this structural phenotype are not known. Analogous with the benefits of a low heart rate on a dilated heart, we hypothesized that increased heart rates could lead to potentially beneficial remodeling of a concentrically hypertrophied LV. This was explored in an established porcine model of concentric LV hypertrophy and fibrosis. Our results suggest that a moderate increase in heart rate can be used to reduce wall thickness, normalize LV chamber volumes, decrease myocardial fibrosis, and improve LV compliance. Our results also indicate that the effects of heart rate can be titrated, are reversible, and do not induce HF. These findings may provide the rationale for a novel therapeutic approach for HFpEF and its antecedent disease substrate.

KW - Heart rate

KW - Hypertrophy

KW - Pacemaker

KW - Remodelling

UR - http://www.scopus.com/inward/record.url?scp=84990041161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990041161&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00301.2016

DO - 10.1152/ajpheart.00301.2016

M3 - Article

C2 - 27591220

AN - SCOPUS:84990041161

VL - 311

SP - H1031-H1039

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 4

ER -